Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule.

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Lee, J. S., Sludden, J., Ferrigan, L. M., Boddy, A. V., Verrill, M. W., Cameron, D.

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 29th Annual San Antonio Breast Symposium

Year of Conference: 2006

Number of Volumes: 1

Pages: S252 no. 5118

Publisher: Breast Cancer Research and Treatment, Springer Netherlands

URL: http://dx.doi.org/10.1007/s10549-006-5678-0

DOI: 10.1007/s10549-006-5678-0

Library holdings: Search Newcastle University Library for this item

Sponsor(s): San Antonio Cancer Institute, Baylor College of Medicine, Cancer Therapy and Research Center, The University of Texas

ISBN:

ePrints